Xeris Biopharma Expects 2025 Revenue to Reach $292 Million
I'm PortAI, I can summarize articles.
Xeris Biopharma Holdings Inc. expects its 2025 revenue to reach $292 million, surpassing the previous guidance of $285-$290 million and marking a 44% increase from the prior year. The company projects fourth quarter and full-year net revenue for Recorlev® to be $45 million and $139 million, respectively. Full-year 2025 financial results and the 2026 outlook will be released on March 2, 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments